Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19

Autores:: Amaya Aponte, Silvia Camila

Tipo de recurso:: Article of investigation

Fecha de publicación:: 2021

Institución:: Universidad Autónoma de Bucaramanga - UNAB

Repositorio:: Repositorio UNAB

Idioma:: spa

id	UNAB2_d9f5f27b70309a7ba304287a983ad083
oai_identifier_str	oai:repository.unab.edu.co:20.500.12749/25740
network_acronym_str	UNAB2
network_name_str	Repositorio UNAB
repository_id_str
dc.title.spa.fl_str_mv	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19
dc.title.translated.eng.fl_str_mv	Ivermectin a drug of indiscriminate use in the management of Covid-19
dc.title.translated.por.fl_str_mv	Ivermectina, uma droga de uso indiscriminado no manejo da Covid-19
title	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19
spellingShingle	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19 Ivermectina Medicamento Patógenos Infecciones Medical sciences Life sciences Ivermectin Medication Pathogens Infections Medical sciences Life sciences Health sciences Ivermectina Medicamentos Patógenos Infecções Ciências médicas Ciências da vida Ciências da saúde Ciencias médicas Ciencias de la vida Ciencias de la salud
title_short	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19
title_full	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19
title_fullStr	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19
title_full_unstemmed	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19
title_sort	Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19
dc.creator.fl_str_mv	Amaya Aponte, Silvia Camila
dc.contributor.author.none.fl_str_mv	Amaya Aponte, Silvia Camila
dc.subject.spa.fl_str_mv	Ivermectina Medicamento Patógenos Infecciones
topic	Ivermectina Medicamento Patógenos Infecciones Medical sciences Life sciences Ivermectin Medication Pathogens Infections Medical sciences Life sciences Health sciences Ivermectina Medicamentos Patógenos Infecções Ciências médicas Ciências da vida Ciências da saúde Ciencias médicas Ciencias de la vida Ciencias de la salud
dc.subject.keywords.eng.fl_str_mv	Medical sciences Life sciences Ivermectin Medication Pathogens Infections Medical sciences Life sciences Health sciences
dc.subject.keywords.por.fl_str_mv	Ivermectina Medicamentos Patógenos Infecções Ciências médicas Ciências da vida Ciências da saúde
dc.subject.lemb.spa.fl_str_mv	Ciencias médicas Ciencias de la vida
dc.subject.proposal.spa.fl_str_mv	Ciencias de la salud
publishDate	2021
dc.date.issued.none.fl_str_mv	2021-08-20
dc.date.accessioned.none.fl_str_mv	2024-07-25T21:12:35Z
dc.date.available.none.fl_str_mv	2024-07-25T21:12:35Z
dc.type.eng.fl_str_mv	Article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.spa.fl_str_mv	Artículo
dc.type.coar.none.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.none.fl_str_mv	http://purl.org/redcol/resource_type/ART
format	http://purl.org/coar/resource_type/c_2df8fbb1
dc.identifier.issn.spa.fl_str_mv	i-ISSN 0123-7047 e-ISSN 2382-4603
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/20.500.12749/25740
dc.identifier.instname.spa.fl_str_mv	instname:Universidad Autónoma de Bucaramanga UNAB
dc.identifier.reponame.spa.fl_str_mv	reponame:Repositorio Institucional UNAB
dc.identifier.repourl.spa.fl_str_mv	repourl:https://repository.unab.edu.co
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.29375/01237047.4195
identifier_str_mv	i-ISSN 0123-7047 e-ISSN 2382-4603 instname:Universidad Autónoma de Bucaramanga UNAB reponame:Repositorio Institucional UNAB repourl:https://repository.unab.edu.co
url	http://hdl.handle.net/20.500.12749/25740 https://doi.org/10.29375/01237047.4195
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.spa.fl_str_mv	https://revistas.unab.edu.co/index.php/medunab/article/view/4195/3446
dc.relation.uri.spa.fl_str_mv	https://revistas.unab.edu.co/index.php/medunab/issue/view/275
dc.relation.references.none.fl_str_mv	Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet [Internet]. 2020;395(10223):514–23. doi: http://dx.doi. org/10.1016/S0140-6736(20)30154-9 Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med [Internet]. 2021;174(1):69–79. doi: https://doi. org/10.7326/M20-5008 Zemkova H, Tvrdonova V, Bhattacharya A, Jindrichova M. Allosteric modulation of ligand gated ion channels by ivermectin. Vol. 63, Physiological Research. 2014. doi: https://doi.org/10.33549/physiolres.932711 Banerjee K, Nandy M, Dalai CK, Ahmed SN. The Battle against COVID 19 Pandemic: What we Need to Know Before we “Test Fire” Ivermectin. Drug Res (Stuttg). 2020;70(8):337-340. doi: https://doi. org/10.1055/a-1185-8913 Instituto Nacional de Vigilancia de Medicamentos y Alimentos - INVIMA. Sistema de Trámites en Línea - Consultas Públicas. 2017. :8082. Available from: http://consultaregistro.invima.gov.co:8082/Consultas/ consultas/consreg_encabcum.jsp Schmith VD, Zhou J, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther [Internet]. 2020;108(4):762–5. doi: https://doi. org/10.1002/cpt.1889 Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 178, 104787. Antiviral Res [Internet]. 2020;178(January):104787. doi: https://doi.org/10.1016/j. antiviral.2020.104787 Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv [Internet]. 2020;(January). doi: https://doi. org/10.1101/2020.06.06.20124461 Ortega-Guillén E, Meneses G, Coila E. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study). CHEST J [Internet]. 2020;159(1):2110–1. doi: https://doi. org/10.1016/j.chest.2020.10.088 Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214– 6. doi: https://doi.org/10.1016/j.ijid.2020.11.191 Camprubí D, Almuedo-Riera A, Martí-Soler HI, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020;15(11 November):1–6. doi: https://doi.org/10.1371/journal.pone.0242184 Behera P, Patro BK, Singh AK, Chandanshive PD, Ravikumar SR, Pradhan SK, et al. Role of ivermectin in the prevention of SARSCoV-2 infection among healthcare workers in India: A matched case-control study. PLoS One [Internet]. 2021;16(2 February):1–12. Available from: http://dx.doi.org/10.1371/journal. pone.0247163 López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial Visual Abstract Supplemental content. JAMA [Internet]. 2021;325(14):1426–35. Available from: https:// jamanetwork.com/ Buonfrate D, Bisoffi Z. Standard Dose Ivermectin for COVID-19. Chest [Internet]. 2021;159(5):2111–2. doi: https://doi.org/10.1016/j.chest.2021.03.003 Zangrillo A. COVID-19 y Argumentum ad ignorantiam o «no todo vale». Rev Clínica Española [Internet]. 2020;10(January):19–21. doi: https://doi.org/10.1016/j. rce.2020.04.013
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.local.spa.fl_str_mv	Abierto (Texto Completo)
dc.rights.creativecommons.*.fl_str_mv	Atribución-NoComercial-SinDerivadas 2.5 Colombia
rights_invalid_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/ Abierto (Texto Completo) Atribución-NoComercial-SinDerivadas 2.5 Colombia http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.grantor.spa.fl_str_mv	Universidad Autónoma de Bucaramanga UNAB
dc.publisher.faculty.spa.fl_str_mv	Facultad Ciencias de la Salud
dc.source.spa.fl_str_mv	Vol. 24 Núm. 2 (2021): agosto-noviembre, 2021: Telemedicina, Neoplasias, Cannabis; 151-154
institution	Universidad Autónoma de Bucaramanga - UNAB
bitstream.url.fl_str_mv	https://repository.unab.edu.co/bitstream/20.500.12749/25740/1/Art%c3%adculo.pdf https://repository.unab.edu.co/bitstream/20.500.12749/25740/3/Art%c3%adculo.pdf.jpg https://repository.unab.edu.co/bitstream/20.500.12749/25740/2/license.txt
bitstream.checksum.fl_str_mv	09ec163cac740de4539263dd65a34939 3dcc2540403c48a8bc311cad787fc4cf 737346e09d47a3db691f1370de49426a
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional \| Universidad Autónoma de Bucaramanga - UNAB
repository.mail.fl_str_mv	repositorio@unab.edu.co
_version_	1814277384326610944
spelling	Amaya Aponte, Silvia Camilaed21f297-e3c5-4db9-bae1-0741f97575ee2024-07-25T21:12:35Z2024-07-25T21:12:35Z2021-08-20i-ISSN 0123-7047e-ISSN 2382-4603http://hdl.handle.net/20.500.12749/25740instname:Universidad Autónoma de Bucaramanga UNABreponame:Repositorio Institucional UNABrepourl:https://repository.unab.edu.cohttps://doi.org/10.29375/01237047.4195application/pdfspahttps://revistas.unab.edu.co/index.php/medunab/article/view/4195/3446https://revistas.unab.edu.co/index.php/medunab/issue/view/275Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet [Internet]. 2020;395(10223):514–23. doi: http://dx.doi. org/10.1016/S0140-6736(20)30154-9Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med [Internet]. 2021;174(1):69–79. doi: https://doi. org/10.7326/M20-5008Zemkova H, Tvrdonova V, Bhattacharya A, Jindrichova M. Allosteric modulation of ligand gated ion channels by ivermectin. Vol. 63, Physiological Research. 2014. doi: https://doi.org/10.33549/physiolres.932711Banerjee K, Nandy M, Dalai CK, Ahmed SN. The Battle against COVID 19 Pandemic: What we Need to Know Before we “Test Fire” Ivermectin. Drug Res (Stuttg). 2020;70(8):337-340. doi: https://doi. org/10.1055/a-1185-8913Instituto Nacional de Vigilancia de Medicamentos y Alimentos - INVIMA. Sistema de Trámites en Línea - Consultas Públicas. 2017. :8082. Available from: http://consultaregistro.invima.gov.co:8082/Consultas/ consultas/consreg_encabcum.jspSchmith VD, Zhou J, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther [Internet]. 2020;108(4):762–5. doi: https://doi. org/10.1002/cpt.1889Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 178, 104787. Antiviral Res [Internet]. 2020;178(January):104787. doi: https://doi.org/10.1016/j. antiviral.2020.104787Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv [Internet]. 2020;(January). doi: https://doi. org/10.1101/2020.06.06.20124461Ortega-Guillén E, Meneses G, Coila E. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study). CHEST J [Internet]. 2020;159(1):2110–1. doi: https://doi. org/10.1016/j.chest.2020.10.088Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214– 6. doi: https://doi.org/10.1016/j.ijid.2020.11.191Camprubí D, Almuedo-Riera A, Martí-Soler HI, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020;15(11 November):1–6. doi: https://doi.org/10.1371/journal.pone.0242184Behera P, Patro BK, Singh AK, Chandanshive PD, Ravikumar SR, Pradhan SK, et al. Role of ivermectin in the prevention of SARSCoV-2 infection among healthcare workers in India: A matched case-control study. PLoS One [Internet]. 2021;16(2 February):1–12. Available from: http://dx.doi.org/10.1371/journal. pone.0247163López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial Visual Abstract Supplemental content. JAMA [Internet]. 2021;325(14):1426–35. Available from: https:// jamanetwork.com/Buonfrate D, Bisoffi Z. Standard Dose Ivermectin for COVID-19. Chest [Internet]. 2021;159(5):2111–2. doi: https://doi.org/10.1016/j.chest.2021.03.003Zangrillo A. COVID-19 y Argumentum ad ignorantiam o «no todo vale». Rev Clínica Española [Internet]. 2020;10(January):19–21. doi: https://doi.org/10.1016/j. rce.2020.04.013http://creativecommons.org/licenses/by-nc-nd/2.5/co/Abierto (Texto Completo)Atribución-NoComercial-SinDerivadas 2.5 Colombiahttp://purl.org/coar/access_right/c_abf2Vol. 24 Núm. 2 (2021): agosto-noviembre, 2021: Telemedicina, Neoplasias, Cannabis; 151-154IvermectinaMedicamentoPatógenosInfeccionesMedical sciencesLife sciencesIvermectinMedicationPathogensInfectionsMedical sciencesLife sciencesHealth sciencesIvermectinaMedicamentosPatógenosInfecçõesCiências médicasCiências da vidaCiências da saúdeCiencias médicasCiencias de la vidaCiencias de la saludIvermectina un medicamento de uso indiscriminado en el manejo del Covid-19Ivermectin a drug of indiscriminate use in the management of Covid-19Ivermectina, uma droga de uso indiscriminado no manejo da Covid-19Articleinfo:eu-repo/semantics/articleArtículohttp://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/coar/resource_type/c_6501http://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85Universidad Autónoma de Bucaramanga UNABFacultad Ciencias de la SaludORIGINALArtículo.pdfArtículo.pdfArtículoapplication/pdf534292https://repository.unab.edu.co/bitstream/20.500.12749/25740/1/Art%c3%adculo.pdf09ec163cac740de4539263dd65a34939MD51open accessTHUMBNAILArtículo.pdf.jpgArtículo.pdf.jpgIM Thumbnailimage/jpeg11867https://repository.unab.edu.co/bitstream/20.500.12749/25740/3/Art%c3%adculo.pdf.jpg3dcc2540403c48a8bc311cad787fc4cfMD53open accessLICENSElicense.txtlicense.txttext/plain; charset=utf-8183https://repository.unab.edu.co/bitstream/20.500.12749/25740/2/license.txt737346e09d47a3db691f1370de49426aMD52open access20.500.12749/25740oai:repository.unab.edu.co:20.500.12749/257402024-07-25 22:01:04.085open accessRepositorio Institucional \| Universidad Autónoma de Bucaramanga - UNABrepositorio@unab.edu.coTGFzIHB1YmxpY2FjaW9uZXMgZGUgbGEgcmV2aXN0YSBNZWRVTkFCIGVzdMOhbiBiYWpvIHVuYSBMaWNlbmNpYSBkZSBBdHJpYnVjacOzbiBkZSBCaWVuZXMgQ29tdW5lcyBDcmVhdGl2b3MgKENyZWF0aXZlIENvbW1vbnMsIENDKSB0aXBvIDQuMCwgY29uIGRlcmVjaG9zIGRlIGF0cmlidWNpw7NuIHkgbm8gY29tZXJjaWFs

Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19

Publicaciones similares